Please assess the completion status of the following clinical trial:

Trial Title: Trial of Aripiprazole in Trichotillomania

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Eligible patients:~* Must be outpatients between the ages of 18 and 65 at the start of study~* May be male or female~* Have DSM-IV trichotillomania of at least 6 months duration~* Allowed psychotropic medications are limited to:~  * SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), SNRIs (duloxetine, venlafaxine) and mirtazapine, as long as the dosage has not changed for 4 weeks prior to study enrollment.~ * Other allowed medications include non-hypnotic sleeping agents, specifically trazodone, diphenhydramine, hydoxyzine and ramelteon.~ * If a patient is taking non-allowed psychotropic medications, he/she must be titrated off by the prescribing physician and be off of the medication for at least 2 weeks prior to trial enrollment.~* We will not exclude patients meeting DSM-IV criteria for:~  * body dysmorphic disorder;~ * major depression;~ * dysthymia;~ * GAD, social phobia, panic disorder.~Exclusion Criteria:~* We will exclude patients suffering from:~  * organic mental disorders;~ * psychotic mental disorders including delusional disorder, somatic type;~ * mental retardation or developmental disabilities;~ * substance or alcohol abuse;~ * depressive disorders with current suicidal risk;~ * factitious disorders;~ * dissociative disorders;~ * obsessive compulsive disorder;~ * personality disorders sufficiently severe to interfere with cooperation with the study;~ * bipolar I or II disorder.~* Patients taking psychotropic agents other than those specifically listed in item d above. If a patient is taking non-allowed psychotropic medications, he/she must be titrated off such medications by the prescribing physician and be off of the medication for 2 weeks prior to trial enrollment.~* Pregnant or nursing women.~* Patients with a known hypersensitivity or allergy to aripiprazole.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open-label aripiprazol (Type: EXPERIMENTAL): Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.

Based on this trial design, predict the completion outcome and termination type (if applicable).